

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

	te Application of: on Park, Stephani		an,	
Seri	al No.:		Group Art Unit:	
Filir	Filing Date: Herewith		Examiner:	
			ING FOR IDENTIFYING MOLE SIS OF METASTATIC CANCER	CULAR
			EXPRESS MAIL LABEL NO: EL659 DATE OF DEPOSIT: March 27, 2001	
Box	☐ Patent Applie	cation		
	☐ Provisional	⊠ Sequence		
	tant Commissioner ington DC 20231	for Patents		
Sir:				
	PATE	NT APPLICATI	ON TRANSMITTAL LETTER	
	Transmitted here	with for filing, ple	ease find	
\boxtimes	A Utility Patent	Application under	37 C.F.R. 1.53(b).	
	It is a continuing	application, as fol	llows:	
	☐ continuation/	divisional [continuation-in-part of prior appli	cation number
	A Provisional Pa	tent Application u	nder 37 C.F.R. 1.53(c).	
	A Design Patent	Application (subm	nitted in duplicate).	
	filed herewith ha country, or under of applications 13	s not and will not it a multilateral inte 8 months after filin	invention(s) disclosed in the present be the subject of an application filed ernational agreement, that requires pung. Thus, pursuant to 35 U.S.C. §122 -identified patent application not be p	in another ablication $2(b)(2)(B)(i)$,

Includ	ling the following:				
	Provisional Application Cover Sheet.				
×	New o	or Revis	sed Specification, including pages 1 to 29 containing:		
	\boxtimes	Speci	fication		
	\boxtimes	Claim	s		
	\boxtimes	Abstra	act		
		Subst	itute Specification, including Claims and Abstract.		
			The present application is a continuation application of Application No filed The present application includes the Specification of the parent application which has been revised in accordance with the amendments filed in the parent application. Since none of those amendments incorporate new matter into the parent application, the present revised Specification also does not include new matter.		
			The present application is a continuation application of Application No, which in turn is a continuation-in-part of Application No, filed The present application includes the Specification of the parent application which has been revised in accordance with the amendments filed in the parent application. Although the amendments in the parent C-I-P application may have incorporated new matter, since those are the only revisions included in the present application, the present application includes no new matter in relation to the parent application.		
	includ matter for su	ling Spe r has be ch earli	rlier application Serial NoFiled, ecification, Claims and Abstract (pages 1 - @@), to which no new en added TOGETHER WITH a copy of the executed oath or declaration er application and all drawings and appendices. Such earlier application proporated into the present application by reference.		
	to Rel	ated Ap	he following amendment to the Specification under the Cross-Reference oplications section (or create such a section): "This Application: nuation of \square is a divisional of \square claims benefit of U.S. provisional Serial Nofiled		

DOC	CKET NO.: TJU-2415 - 3 - PATENT
	Signed Statement attached deleting inventor(s) named in the prior application.
	A Preliminary Amendment.
\boxtimes	Five (5) Sheets of Formal Drawings.
	☐ Drawing view to publish: Figure
	Petition to Accept Photographic Drawings.
	☐ Petition Fee
\boxtimes	An \square Executed \boxtimes Unexecuted Declaration or Oath and Power of Attorney.
	An Associate Power of Attorney.
	An Executed Copy of Executed Assignment of the Invention to
	A Recordation Form Cover Sheet.
	Recordation Fee - \$40.00.
	The prior application is assigned of record to
	Priority is claimed under 35 U.S.C. § 119 of Patent Application No.
	filed in (country).
	A Certified Copy of each of the above applications for which priority is claimed:
	is enclosed.
	has been filed in prior application Serial No filed
	Please enter the following amendment to the first sentence of the specification (or create such a sentence): "This application claims benefit of international application No, which was published under PCT Article 21(2) in English."
\boxtimes	Applicant(s) by its/their undersigned attorney, claims small entity status under 37 C.F.R. §1.27 as:

 \boxtimes

Form of Sequence Listing.

	DOC	KET NO. : TJU-2415	- 4 -	PATENT
		an Independent Invent	or	
		☐ a Small Business Cond Inc.)	eern (as it pertains to Targeted	Diagnostics & Therapeutics,
		a Nonprofit Organizati	on (as it pertains to Thomas Je	efferson University)
	\boxtimes	Diskette Containing DNA	Amino Acid Sequence Inform	aation.
	\boxtimes	Statement to Support Subr	nission of DNA/Amino Acid S	Sequence Information.
And then then than their than their is N theor breit is " tadd finds that		Application Serial Number 1.821(e), please use the form filed in that application application. It is understoon necessary change in application that will be used for the Listing is included in the	m in this application	only computer readable orm for the instant ork Office will make the or the computer readable or copy of the Sequence of the instant application,
A)** * * * * * * * * * * * * * * * * * *		Information Disclosure Sta Attached Form 144 Copies of each of the enclosed herewith.		ched Form PTO-1449 are
		A copy of Petition for Exte	ension of Time as filed in the p	rior case.
		Appended Material as follo	ows:	
	\boxtimes	Return Receipt Postcard (s	hould be specifically itemized).

Other as follows: Paper Copy of Sequence Listing - Pages 1 to 2; Computer Readable

DOCKET NO. : TJU-2415	- 5 -	PATENT
DOCKER INCOME	•	*******

FEE CALCULATION:

Cancel in this application or	iginal claims	of the prior application before
calculating the filing fee. (A	At least one original indeper	ndent claim must be retained
for filing purposes.)		

			SMALL	ENTITY	NOT SMA	ALL ENTITY
			RATE	FEE	RATE	FEE
PROVISIONAL AI			\$75.00	\$	\$150.00	\$
DESIGN APPLICA	TION		\$160.00	\$	\$320.00	\$
UTILITY APPLICA	ATIONS BASE FE	EE	\$355.00	\$355.00	\$710.00	\$
UTILITY APPLICATED AN AMENDMENTS						
	No. Filed	No. Extra				
TOTAL CLAIMS	15- 20 =	0	\$9 each	\$0	\$18 each	\$
INDEP. CLAIMS	1-3=	0	\$40 each	\$0	\$80 each	\$
FIRST PRESENTATION OF MULTIPLE DEPENDENT CLAIM			\$135	\$0	\$270	\$
ADDITIONAL FILING FEE				\$		\$
TOTAL FILING FEE DUE				\$355.00		\$

 \triangle A Check is enclosed in the amount of \$355.00.

The Commissioner is authorized to charge payment of the following fees and to refund any overpayment associated with this communication or during the pendency of this application to deposit account 23-3050. This sheet is provided in duplicate.

☐ The foregoing amount due.

Any additional filing fees required, including fees for the presentation of extra claims under 37 C.F.R. 1.16.

Any additional patent application processing fees under 37 C.F.R. 1.17 or 1.20(d).

The Commissioner is hereby requested to grant an extension of time for the appropriate length of time, should one be necessary, in connection with this filing or any future filing submitted to the U.S. Patent and Trademark Office in the above-identified application during the pendency of this application. The Commissioner is

further authorized to charge any fees related to any such extension of time to deposit account 23-3050. This sheet is provided in duplicate.

SHOULD ANY DEFICIENCIES APPEAR with respect to this application, including deficiencies in payment of fees, missing parts of the application or otherwise, the United States Patent and Trademark Office is respectfully requested to promptly notify the undersigned.

Date: 3/21/01

Mark DeLuca

Registration No. 33,229

Woodcock Washburn Kurtz Mackiewicz & Norris LLP One Liberty Place - 46th Floor Philadelphia PA 19103 Telephone: (215) 568-3100

Facsimile: (215) 568-3439

©2000 WWKMN

DOCKET NO.: TJU-2415 PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of: Scott A. Waldman,

Jason Park, Stephanie Schulz

Serial No.:

Group Art Unit:

Filing Date: Herewith

Examiner:

USE OF EXPRESSION PROFILING FOR IDENTIFYING MOLECULAR MARKERS USEFUL FOR DIAGNOSIS OF METASTATIC CANCER

BOX SEQUENCE

Assistant Commissioner for Patents Washington DC 20231

STATEMENT TO SUPPORT FILING AND SUBMISSION IN ACCORDANCE WITH 37 CFR §§ 1.821 THROUGH 1.825

X	I hereby state, in accordance with the requirements of 37 C.F.R. §1.821(f), that the
	contents of the paper and computer readable copies of the Sequence Listing, submitted in accordance with 37 CFR §1.821(c) and (e), respectively are the same.
	I hereby state that the submission filed in accordance with 37 CFR §1.821(g) does not include new matter.
	I hereby state that the submission filed in accordance with 37 CFR §1.821(h) does not include new matter or go beyond the disclosure in the international application as filed.
	I hereby state that the amendments, made in accordance with 37 CFR §1.825(a), included in the substitute sheet(s) of the Sequence Listing are supported in the application, as filed, at pages I hereby state that the substitute sheet(s) of the Sequence Listing does (do) not include new matter.
	I hereby state that the substitute copy of the computer readable form, submitted in accordance with 37 CFR §1.825(b), is the same as the amended Sequence Listing.
	I hereby state that the substitute copy of the computer readable form, submitted in accordance with 37 CFR §1.825(d), contains identical data to that originally filed.
Date:	R/27/01 Mark Del uca

Registration No. 33,229

Woodcock Washburn Kurtz Mackiewicz & Norris LLP One Liberty Place - 46th Floor Philadelphia PA 19103 Telephone: (215) 568-3100

Facsimile: (215) 568-3439

© 1997 WWKMN